Directory
Antonia Salud Salvia

Antonia Salud Salvia

Degree: PhD


masalud.lleida.ics(ELIMINAR)@gencat.cat

Groups

Publications

  • Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F

    Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab

    Journal of Clinical Oncology 31 4445-4445. .

    [doi:10.1200/JCO.2013.48.9070]

  • Marquez-Medina D; Chachoua A; Martin-Marco A; Desai AM; Garcia-Reglero V; Salud-Salvia A; Muggia F

    Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?

    CLINICAL & TRANSLATIONAL ONCOLOGY 15 959-964. .

    [doi:10.1007/s12094-013-1035-z]

  • Canal Sotelo, Jaume; Barallat Gimeno, Eva; Martin Marco, Antonio; Salud Salvia, Antonieta

    Painful mouth and stomatitis due to a herpes simplex virus type 1 infection

    MEDICINA PALIATIVA 20 158-159. .

    [doi:10.1016/j.medipa.2012.05.008]

  • Márquez-Medina D; Gasol-Cudós A; Taberner-Bonastre MT; Samamé Pérez-Vargas JC; Salud-Salvia A; Llombart-Cussac A

    Human Papillomavirus in Non-Small-Cell Lung Cancer: The Impact of EGFR Mutations and the Response to Erlotinib

    ARCHIVOS DE BRONCONEUMOLOGIA 49 79-81. .

    [doi:10.1016/j.arbres.2012.04.003]

  • Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S

    Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

    LANCET ONCOLOGY 14 29-37. .

    [doi:10.1016/S1470-2045(12)70477-1]

  • Muñoz A; Pericay C; García-Girón C; Alonso V; Dueñas R; Cirera L; Rivera F; Falcó E; Bustos IA; Salud A

    Phase II Study of Bevacizumab, Capecitabine, and Oxaliplatin Followed by Bevacizumab Plus Erlotinib as First-Line Therapy in Metastatic Colorectal Cancer

    ONCOLOGY RESEARCH 21 181-191. .

    [doi:10.3727/096504014X13887748696743]

  • Marquez-Medina, Diego; Salla-Fortuny, Joel; Salud-Salvia, Antonieta

    Role of gamma-delta T-cells in cancer. Another opening door to immunotherapy

    CLINICAL & TRANSLATIONAL ONCOLOGY 14 891-895. .

    [doi:10.1007/s12094-012-0935-7]

  • Gravalos, Cristina; Salut, Antonieta; Garcia-Giron, Carlos; Garcia-Carbonero, Rocio; Isabel Leon, Ana; Sevilla, Isabel; Maurel, Joan; Esteban, Beatriz; Garcia-Rico, Eduardo; Murias, Adolfo; Cortes-Funes, Hernan

    A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer

    CLINICAL & TRANSLATIONAL ONCOLOGY 14 606-612. .

    [doi:10.1007/s12094-012-0843-x]

  • Anton, A.; Montalar, J.; Carulla, J.; Jara, C.; Batista, N.; Camps, C.; Cassinello, J.; Sanz-Ortiz, J.; Diaz-Rubio, E.; Martinez, C.; Ledesma, F.; Zubillaga, E.; ALGOS Grp; DOME III Study Grp

    Pain in clinical oncology: Patient satisfaction with management of cancer pain

    EUROPEAN JOURNAL OF PAIN 16 381-389. .

    [doi:10.1002/j.1532-2149.2011.00036.x]

  • Maria Vieitez, Jose; Garcia-Carbonero, Rocio; Aparicio, Jorge; Feliu, Jaime; Gonzalez-Flores, Encarnacion; Grande, Enrique; Perez-Hoyos, Teresa; Salud, Antonieta; Torres, Esperanza; Valero, Maria; Valladares-Ayerbes, Manuel; Diaz-Rubio, Eduardo

    Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain.

    CLINICAL & TRANSLATIONAL ONCOLOGY 13 798-804. .

    [doi:10.1007/s12094-011-0736-4]

  • Nogue, Miguel; Salud, Antonieta; Vicente, Pilar; Arrivi, Antonio; Maria Roca, Jose; Losa, Ferran; Ponce, Jose; Jose Safont, Maria; Guasch, Inmaculada; Moreno, Isabel; Ruiz, Ana; Pericay, Carles

    Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.

    Oncologist 16 614-620. .

    [doi:10.1634/theoncologist.2010-0285]

  • Bielsa, Silvia; Hernandez, Paula; Rodriguez-Panadero, Francisco; Taberner, Teresa; Salud, Antonieta; Porcel, Jose M.

    Tumor type influences the effectiveness of pleurodesis in malignant effusions.

    Lung 189 151-155. .

    [doi:10.1007/s00408-011-9283-6]

Projects

  • Decodificación de la metástasis del cáncer colorrectal desentrañando el señalosoma de PLA2G12A
  • Ajuts per a la contractació de personal investigador novell (FI)
  • Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
  • Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
  • UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
  • Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante